GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hunan Fangsheng Pharmaceutical Co 603998.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.23

-0.68%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hunan Fangsheng Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603998.SS. It has been listed since 5 December 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.75bn and net income of CN¥306.4m. At that date it held total assets of CN¥3.06bn and shareholders' equity of CN¥1.71bn.

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in the manufacture, distribution, research and development of pharmaceutical products. The company is headquartered in Changsha, Hunan. The company went IPO on 2014-12-05. The firm's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The firm distributes its products primarily in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
5 Dec 2014
Employees
1,600

Leadership

Pay as last reported

  • Ms. Xiaoli ZhouChairman of the Board, General Manager, since 2022
  • Ms. Xiangqi CaoChief Financial Officer
  • Mr. Bo ChenDeputy General Manager, Director, since 2015
  • Mr. Jianjun GuoAssistant to the General Manager
  • Mr. Shi HeSecretary of the Board
  • Mr. Yue XiaoDirector
  • Ms. Shouying DuIndependent Director
  • Mr. Xuemin GaoIndependent Director
  • Mr. Xiong YuanIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Hunan Fangsheng employs 1600 employees in Changsha for pharmaceutical manufacturing and R&D.
  • Xuesaitong Dispersible Tablets and Xuesaitong Tablets are key products in the domestic market.
  • The company's IPO on 5 December 2014 established a strong market presence.

Weaknesses

  • The company focuses solely on the domestic market without international expansion.
  • Xuesaitong Dispersible Tablets and Xuesaitong Tablets face competition in the Chinese pharmaceutical market.
  • Hunan Fangsheng lacks global distribution channels for its pharmaceutical products.

Opportunities

  • Expanding into international markets could increase the company's market share.
  • Growing demand for traditional Chinese medicine products presents new opportunities.
  • The domestic market's increasing healthcare spending supports pharmaceutical growth.

Threats

  • Intense competition from other Chinese pharmaceutical companies threatens market share.
  • Regulatory changes in the Chinese healthcare sector could impact product approvals.
  • Economic downturns in China may reduce consumer spending on pharmaceuticals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.